Rockwell plans to conduct $55 million public offering of common stock

Bookrunner BofA Merrill Lynch and lead manager Stifel assist with deal

By Devika Patel

Knoxville, Tenn., Nov. 17 – Rockwell Medical, Inc. will price a $55 million public sale of common stock with a 30-day $8.25 million greenshoe, according to a preliminary prospectus supplement and 8-K filed Monday with the Securities and Exchange Commission.

BofA Merrill Lynch is the bookrunner, Stifel is the lead manager, and Summer Street, Craig-Hallum, Chardan Capital Markets, LLC and LifeSci Capital are the co-managers.

Proceeds will be used to prepay debt under the company’s loan and security agreement with Hercules Technology III, LP, for general corporate purposes, including working capital, research and development expenses, acquisitions of intellectual property and general and administrative expenses.

Wixom, Mich.-based Rockwell Medical is a manufacturer and developer of renal drug therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.